You are here

P&T® Journal contents for November 2008


Cover Story
Heparin is a valuable anticoagulant, but it can induce severe immunologic ­reactions at any dose. The authors present a comprehensive review of the pathophysiology, etiology, diagnosis, laboratory findings, and therapeutic management of thrombocytopenia that can result from this antithrombotic agent.
Daniel A. Zinkovsky, PharmD, and Marilena S. Antonopoulos, PharmD, FASCP
In an evaluation of patients who were switched from fixed-dose combination (FDC) to free-combination (FC) therapy for elevated blood pressure, the authors found that patients continuing with the FDC regimen had better persistence and compliance compared with patients who were switched to FC therapy. Greater compliance with the FDC regimen was also associated with lower health care costs and with less use of health care–related resources.
Gregory Hess, MD, MBA; Jerrold Hill, PhD; Helen Lau, MS; Homa Dastani, PhD; and Paresh Chaudhari, PharmD, MPH
Meeting Highlights
Some of the topics covered at this oncology meeting included cetuximab (Erbitux) for colorectal cancer, pazopanib and antibody CP-751871 for non–small-cell lung cancer; Everolimus (Certican) for pancreatic tumors; lapatinib (Tykerb) for squamous cell carcinoma; and Elesclomol for melanoma. Denosumab and odanacatib, presented at the bone and mineral research meeting, were found to increase bone density and build new bone.
Walter Alexander
Romiplostim (Nplate) for thrombocytopenia; palonosetron capsules (Aloxi) for chemotherapy-induced nausea and vomiting; and iobenguane iodine-123 injection (AdreView), used for diagnosing primary or metastatic pheochromo­cytoma or neuroblastoma as an adjunct to other tests, are discussed.
Marvin M. Goldenberg, PhD, RPh, MS


David Nash, MD, MBA, muses on the gloomy mood of Moody’s Investor Services.
David B. Nash, MD, MBA
Medication Errors
Applying the Joint Commission’s “Two-Identifier” Rule Goes beyond the Patient’s Room
Matthew Grissinger, RPh, FASCP, explains how the Joint Commission’s “two-identifer” rule can help prevent patient mixups.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the Drug Enforcement Agency’s proposal to allow electronic prescribing of Schedule II–V controlled substances in order to reduce diversion of these agents.
Stephen Barlas
From Cinryze to Vaprisol, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Authors Kisgen and Whitney review ceftobiprole, a cephalosporin for methicillin-resistant Staphylococcus aureus (MRSA) infection.
Jamie Kisgen, PharmD, and Dana Whitney, PharmD, BCPS